 Cohorts of 3-6 patients with solid tumors receive escalating doses of FR901228 until the maximum tolerated dose MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. 